The majority of the potential drugs for Alzheimer’s disease have targeted the metabolism of the C-terminal part of amyloid precursor protein (C99-APP) [2,4,5,6]. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.